Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Jun 6, 2025--
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today presented results from a pre-specified interim analysis of the Phase 3 VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. Patients treated with sibeprenlimab achieved a 51.2% (P<0.0001) reduction in proteinuria (as measured by 24-hour uPCR [urine protein-to-creatinine ratio]) at nine months of treatment when compared to placebo 1. The data were presented during a late-breaking clinical trials session at the European Renal Association (ERA) Congress in Vienna, Austria. The study, the largest Phase 3 IgAN trial conducted to date, also showed the safety profile of sibeprenlimab was favorable and consistent with previously reported data 1. Specifically, 76.3% of patients treated with sibeprenlimab experienced any Treatment Emergent Adverse Event (TEAE) versus 84.5% in the placebo group. 1 Patients who experienced a serious TEAE were 3.9% treated with sibeprenlimab compared to 5.4% treated with placebo.
Sibeprenlimab received Priority Review designation from the FDA last month following its BLA filing in March. Proteinuria reduction is a recognized surrogate marker correlating with delaying progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated regulatory approvals 2.
Sibeprenlimab is an investigational monoclonal antibody that selectively inhibits the activity of APRIL (A PRoliferation-Inducing Ligand) in adults with IgAN. APRIL plays a key role in the 4-hit process of IgAN pathogenesis and is an important initiating and sustaining factor in IgAN progression by promoting the production of pathogenic Gd-IgA1 and immune complex formation 3,4,5,6. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels 1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation 7. Sibeprenlimab is administered in a single-dose prefilled syringe for subcutaneous injection every four weeks intended for self-administration or administration by caregiver, providing patients the option of convenience at home.
'We are confident about the potential of sibeprenlimab and are grateful to the patients who are helping to further the science by participating in these important trials,' said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka Pharmaceutical Development & Commercialization, Inc. 'Proteinuria control is an important independent predictor for long-term prognosis, and this interim data reinforces our belief that selectively targeting APRIL has the potential to be an effective and safe approach for this progressive and irreversible kidney disease.'
The VISIONARY study continues in a blinded manner to evaluate the change in kidney function over 24 months as measured by estimated glomerular filtration rate (eGFR) and is expected to be completed in early 2026. Further prespecified and exploratory analyses of the data will be conducted to determine the full potential of sibeprenlimab for the treatment of IgAN 1.
'The VISIONARY Phase 3 interim analysis shows a robust proteinuria reduction of 51.2% in the group treated with sibeprenlimab relative to placebo. These results affirm our belief in the efficacy of sibeprenlimab in the largest Phase 3 IgAN trial to date. The study enrolled a diverse patient population reflective of the disease epidemiology,' said Dr. Dana Rizk, professor of medicine in the division of nephrology at the University of Alabama at Birmingham. 'The safety data emerging from VISIONARY is reassuring and adds to our existing knowledge about sibeprenlimab's safety profile from prior programs. This is very exciting news for patients and adds a therapeutic option with a novel mechanism of action potentially targeting the immunologic pathogenesis of IgAN.'
About the VISIONARY Study
The VISIONARY study is the largest IgAN trial to date, and is a multicenter, randomized, double-blind, placebo-controlled trial consisting of approximately 510 adult patients with IgAN who were receiving standard-of-care therapy (defined as maximally tolerated ACE inhibitor or ARB +/- SGLT2 inhibitor), designed to evaluate the efficacy and safety of sibeprenlimab 400 mg administered subcutaneously every four weeks, compared to placebo 1. The primary efficacy endpoint is to evaluate the change in 24-hour uPCR at 9 months compared with baseline. The secondary endpoint is to evaluate the annualized slope of eGFR estimated over ~24 months 1.
About Sibeprenlimab
Sibeprenlimab (formerly VIS649) was designed and engineered by Visterra, Inc., a wholly owned subsidiary of Otsuka. Pre-clinical and early-stage trials of sibeprenlimab were also conducted by Visterra. Sibeprenlimab is an investigational monoclonal antibody that selectively binds to and inhibits the activity of APRIL and plays a key role in the 4-hit process. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels 1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation 7. Decreased immune complex formation should result in diminished deposition in the kidney, and reduced proteinuria and kidney inflammation 8. By reducing the production of Gd-IgA1, sibeprenlimab may help slow kidney damage and progression toward ESKD 3,4,5,6. By inhibiting APRIL, sibeprenlimab may help address one of the IgAN-specific drivers for nephron loss.
About IgAN and APRIL
IgAN is a progressive, immune-mediated, chronic kidney disease that typically manifests in adults aged 20-40 years and leads to ESKD over the lifetime of most patients 9,10,11.
IgAN is characterized by the accumulation of Gd-IgA1 complexes in the kidneys. IgAN can lead to progressive loss of kidney function and, eventually, ESKD, imposing a significant burden on patients 10. Despite supportive care, there is an unmet need for treatments that address the root causes of the condition. Continued research in the disease remains crucial to uncovering opportunities for advancement in our understanding and treatment of patients 5.
APRIL, a cytokine in the tumor necrosis factor (TNF) family, is integral to the pathogenesis and progression of IgAN. It promotes the survival and class switching of B cells to produce IgA, particularly the pathogenic galactose-deficient IgA1 (Gd-IgA1) that forms immune complexes in the kidneys 5.
About Otsuka
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsuka–people creating new products for better health worldwide. Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a 'big venture' company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies' 2,250 employees in the U.S. develop and commercialize medicines in the areas of mental health and nephrology, using cutting-edge technology to address unmet healthcare needs.
OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Co., Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 35,340 people worldwide and had consolidated sales of approximately USD 14.7 billion in 2024.
All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.'s global website is accessible at https://www.otsuka.co.jp/en/.
About Visterra
Visterra is a biologics research and early-stage clinical development biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with immune-mediated kidney diseases and other hard-to-treat diseases. Its proprietary Hierotope® platform enables the design and engineering of precision biologics-based product candidates that specifically bind to, and modulate, key disease targets that are not adequately addressed by traditional therapeutic approaches. The platform also includes Fc engineering capabilities for half-life extension, bispecific antibodies and antibody-drug conjugates (ADCs). Visterra's pipeline includes programs targeting kidney diseases, immunologically-driven diseases and infectious diseases. Visterra is an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd. For more information, visit www.visterrainc.com.
References
View source version on businesswire.com:https://www.businesswire.com/news/home/20250606873555/en/
CONTACT: Contacts for MediaOtsuka in the U.S.Robert Murphy
Corporate Communications
Otsuka America Pharmaceutical, Inc.
[email protected]+1 609 249 7262Otsuka in JapanJeffrey Gilbert
Leader, Pharmaceutical PR
Otsuka Pharmaceutical Co., Ltd.
[email protected]+81 3 6361 7379
KEYWORD: UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC NEW JERSEY
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH FDA CLINICAL TRIALS OTHER HEALTH
SOURCE: Otsuka Pharmaceutical Co., Ltd.
Copyright Business Wire 2025.
PUB: 06/06/2025 06:00 AM/DISC: 06/06/2025 05:58 AM
http://www.businesswire.com/news/home/20250606873555/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
25 minutes ago
- Bloomberg
Austria Rating Cut to Record Low by Fitch as Budget Woes Persist
Austria 's sovereign credit was cut by Fitch Ratings to two steps below the top mark for the first time, handing the government another setback in its bid to repair the country's finances. Fitch lowered Austria's rating to AA with a stable outlook from AA+, according to a statement Friday. Austria's deficit was higher than forecast 'driven by a worse economic environment and overspending at the local government and municipality level,' the ratings firm said.
Yahoo
40 minutes ago
- Yahoo
RFK Jr. will ‘end the war' against alternative medicine at the FDA, from stem cell therapy to chelation. Here's what to know
Health and Human Services Secretary Robert F. Kennedy, Jr. doubled down on his support for non-pharmaceutical health treatments during a recent podcast appearance, saying, 'We're going to end the war at the FDA against alternative medicine.' Speaking on the Ultimate Human podcast with host Gary Brecka, a 'renowned Human Biologist, biohacker, and longevity expert,' according to the website, Kennedy said he would fix the U.S. Food and Drug Administration's bias against the following: stem cell treatments, chelating drugs, vitamins and minerals, amino acids, peptides, and hyperbaric chambers. 'Our position is that the FDA has a job: Just do the science on these kinds of issues and then tell the public what they've learned from the science … but don't tell physicians what they can and cannot prescribe,' he said. And as far as the patients go, he said, 'If you want to take an experimental drug … you ought to be able to do that.' RFK Jr. added, 'We don't want to have the Wild West. We want to make sure that information is out there. But we also want to respect the intelligence of the American people' to decide what treatments will benefit them the most. He acknowledged that, with this approach, there will be 'charlatans' as well as 'people who have bad results' from various alternative treatments. 'But ultimately,' he said, 'you can't prevent that either way, and leaving the whole thing in the hands of pharma is not working for us.' Brecka called Kennedy's pronouncements 'music to my ears.' Below, what you need to know about the alternative therapies RFK Jr. is advocating for. What is it: It's a way to repair diseased or injured tissue in the body using stem cells—cells that can self-renew or become other types of tissues—typically grown in a lab, manipulated, and then be implanted into the patient. What it does: Though it's considered to be largely experimental, the FDA does permit stem cell therapies for blood and immune disorders. Leukemia, lymphoma, neuroblastoma, and multiple myeloma, for example, are also often treated this way, with bone marrow treatments, which are backed by decades of science. Other types of the treatment are still in clinical trials, while more and more wellness centers are offering the treatment for unapproved reasons, using cells drawn from the patient's body and injected back in without manipulation for everything from autism and ALS to Parkinson's and better skin, according to the New York Times. Kennedy told Brecka that he received the treatment for his voice disorder, spasmodic dysphonia, and that it helped him 'enormously,' but that he had to go to Antigua to access it. Risks: For starters, wellness clinic treatments cannot guarantee they are using actual stem cell, reported the Times. And improper injections can lead to a host of terrible consequences—clots, infections, blindness, and even the formation of tumors, which the FDA warned of in 2021. What it is: Chelation involves the use of certain chemicals to remove toxic heavy metals, such as mercury and lead, from the body; all FDA-approved chelation therapy products require a prescription and can only be used safely under the supervision of a healthcare practitioner. What it does: Some alternative medicine practitioners offer chelation therapy, through pill or injection, as a way to treat Alzheimer's, autism, diabetes, high blood pressure, or Parkinson's disease, all of which are unapproved and risky. Children's Health Defense, founded by Kennedy, has written about chelation as a way to treat autism, which compares 'autism with mercury poisoning' due to childhood vaccines that contained the preservative thimerosal (largely mercury) before it was removed in 2001. Some flu shots still contain the preservative, but, says the Centers for Disease Control and Prevention, 'There is no evidence of harm caused by the low doses of thimerosal in vaccines.' Risks: The FDA warns specifically about using chelation therapy for autism, and notes, 'Chelating important minerals needed by the body can lead to serious and life-threatening outcomes.' While minor risks may include fever, headache, muscle pain, and nausea or vomiting, severe reactions range from heart failure and kidney damage to respiratory failure and seizures, according to the Cleveland Clinic. What they are: Dietary supplements in almost every letter of the alphabet, from A to zinc, are over-the-counter pills or liquids that contain nutritional boosts of vitamins and minerals. What they aim to help: Vitamin and mineral supplements aim to fill in with necessary nutrients that a person is not getting through food—though nutritionists believe that healthy food is the best source of such vitamins and minerals. Studies have found supplements may help with practically any issue under the sun—energy, heart issues, cognitive function, gut health, sleep, and more. Risks: The U.S. Food and Drug Administration regulates supplements, but doesn't approve them for safety or effectiveness before they are sold to the public. Some may cause liver damage and toxicity, while others may just be a waste of money. What it is: Amino acids are often referred to as the 'building blocks of proteins,' needed for building proteins, hormones, and neurotransmitters. are compounds that play many critical roles in your body. You need them for vital processes such as building proteins, hormones, and neurotransmitters. Amino acids are concentrated in protein-rich foods such as meat, fish, and soybeans, and foods that contain all nine essential amino acids are called complete proteins. Peptides are short proteins, and come in the form of hormones such as follicle-stimulating hormone (FSH), and creatine and collagen. What they aim to help: Amino acid supplements may help with various issues—such as L-arginine for blood flow and inflammation; tryptophan for mood and sleep; and valine, leucine, and isoleucine to help with energy and athletic performance. Taking collagen supplements may help strengthen nails and bones, while people take creatine for boosting workouts and building muscle growth. Risks: Side effects of taking either can range from toxicity and gastrointestinal issues to effects on brain function muscle protein balance. Creatine may cause muscle cramps and digestive problems (and may not have many benefits), while tryptophan may cause dizziness, headache, or nausea. And again, as with all supplements, the U.S. Food and Drug Administration regulates them, but doesn't approve them for safety or effectiveness before they are sold to the public. What it is: Hyperbaric oxygen therapy in a medical-grade, FDA-approved chamber lets you breathe pure oxygen—as opposed to everyday air, which is just 21% oxygen mixed with nitrogen. Hyperbaric oxygen is also highly pressurized, thereby allowing the lungs to take more in. Home chambers (used by folks including Lebron James, LeAnn Rimes, and Mayim Bialik), as well as those offered in many wellness clinics, do not deliver 100% oxygen. Instead, they use regular air that is 30% more pressurized than normal for what's known as 'mild hyperbarics.' What it aims to help: The FDA has been regulating HBOT chambers since 1976, and has officially cleared 13 medical conditions—such as decompression sickness, burns, radiation injury, and certain wounds—for such treatment. But it's used off-label for many other reasons, including concussions, traumatic brain injury, long COVID, age reversal, stroke recovery, fibromyalgia, and improved brain function, many of which are being looked at in ongoing clinical trials. Risks: For medical-grade chambers, risks include ear and sinus pain, middle ear injuries, temporary vision changes, and lung collapse, which is rare, according to the FDA. For mild hyperbarics, risks include potential exposure to toxic oils from some compressors, carbon dioxide buildup that brings a risk of hypoxia inside the chamber—or, according to some experts and a body of inconclusive evidence, that the treatment may simply be ineffective. This story was originally featured on
Yahoo
an hour ago
- Yahoo
Popular Aldi snack recalled due to potential ‘life-threatening' allergen
Aldi is recalling one of its sweet treats due to the presence of an undeclared allergen. The U.S. Food and Drug Administration (FDA) issued a notice on Tuesday to announce that Camerican International was recalling 7.05 oz boxes of Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream. The recall was issued because the Aldi brand snack may contain undeclared milk, so consumers with an allergy or 'severe sensitivity to milk run the risk of serious or life-threatening allergic reaction,' per the FDA. The recalled churro bites were distributed at Aldi stores in 13 states: Alabama, Arkansas, Florida, Georgia, Iowa, Illinois, Kentucky, Louisiana, Missouri, Mississippi, North Carolina, South Carolina, and Tennessee. The 7.05 oz cardboard boxes are marked with a 'Best If Used By' date of July 14, 2025, and the Lot Number '01425.' According to the FDA, the recall was initiated after a 'consumer discovered that the milk-containing product was distributed in packaging that did not reveal the presence of milk.' A subsequent investigation revealed the mistake was a result of a 'temporary breakdown in the company's production and packaging processes,' which has since been corrected. However, there have been no illnesses reported to date due to this product. Consumers are now urged to return the churro bites to the place of purchase for a full refund. This isn't the first time Aldi food item to be recalled recently. In May, Santa Monica Seafood of Rancho Dominguez, California, issued a voluntary recall on its Atlantic Salmon Portions with Seafood Stuffing because they may have contained undeclared soy. The affected salmon portions were sold in three states: California, Nevada, and Arizona. The products were sold in 16-ounce packages and had a use/freeze-by date of June 2, 2025. The last two years have also seen an alarming and unexplained rise in recalls. In 2024, approximately 300 food recalls were issued, with those recalls being linked to nearly 1,400 illnesses, a Public Interest Research Group report revealed. Out of the 1,400 illnesses, 487 people became sick enough to require hospitalization, and 19 people died. While those numbers are still low when weighed against the entire U.S. population, they are also double the number of hospitalizations and deaths from food-borne illnesses in 2023. Earlier in May, cucumbers sold across the country were recalled after people in 15 states reported getting ill from salmonella. Florida-based Bedner Growers, Inc. recalled the vegetables distributed by Fresh Start Produce Sales, Inc. from April 29 to May 19.
